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Inhibition of ceramide synthesis prevents diabetes,
steatosis, and cardiovascular disease in rodents.
Six different ceramide synthases (CerS) that differ
in tissue distribution and substrate specificity ac-
count for the diversity in acyl-chain composition of
distinct ceramide species. Haploinsufficiency for
ceramide synthase 2 (CerS2), the dominant isoform
in the liver that preferentially makes very-long-chain
(C22/C24/C24:1) ceramides, led to compensatory in-
creases in long-chain C16-ceramides and conferred
susceptibility to diet-induced steatohepatitis and in-
sulin resistance. Mechanistic studies revealed that
these metabolic effects were likely due to impaired
b-oxidation resulting from inactivation of electron
transport chain components. Inhibiting global cer-
amide synthesis negated the effects of CerS2
haploinsufficiency in vivo, and increasing C16-ce-
ramides by overexpressing CerS6 recapitulated the
phenotype in isolated, primary hepatocytes. Collec-
tively, these studies reveal that altering sphingolipid
acylation patterns impacts hepatic steatosis and
insulin sensitivity and identify CerS6 as a possible
therapeutic target for treating metabolic diseases
associated with obesity.
INTRODUCTION
In the obese, the oversupply of saturated fats to nonadipose
tissues coupled with mild inflammation produces ceramides,
which induce metabolic dysfunction (e.g., insulin resistance)
associated with diabetes and cardiovascular disease (Bikman
and Summers, 2011; Chavez and Summers, 2012). Pharmaco-
logical or genetic inhibition of enzymes driving global ceramide
synthesis ameliorates atherosclerosis, steatosis, insulin resis-Celltance, type 2 diabetes, hypertension, and cardiomyopathy,
and enzymes controlling ceramide production have emerged
as attractive therapeutic targets for treating diseases associated
with obesity (Bikman and Summers, 2011; Chavez and Sum-
mers, 2012). However, as ceramides and their sphingolipid prod-
ucts are involved in multiple fundamental cellular processes,
concerns exist about possible risks or adverse effects resulting
from global inhibition of sphingolipid synthesis for treatment of
chronic diseases.
Ceramides, which are precursors of complex sphingolipids,
are comprised of a sphingosine backbone coupled to different
acyl-chains through an amide linkage. A family of at least six
different (dihydro) ceramide synthases (CerS) catalyze the acyl-
ation step, and these isoforms differ in tissue distribution and
substrate specificity (Stiban et al., 2010). Little is known about
whether the acyl-chain alters the functional properties or location
of ceramides, though knockout of the various CerS produces
disparate phenotypes (Ebel et al., 2013; Ginkel et al., 2012; Im-
grund et al., 2009; Jennemann et al., 2012; Pewzner-Jung
et al., 2010a, 2010b; Zhao et al., 2011).
Should one be able to determine which of the synthases pro-
duce the ceramides that contribute to metabolic disease, inhib-
itors of CerS isoforms could ameliorate features of metabolic
disease without posing the health risks predicted for global
blockade of ceramide synthesis. Herein we describe studies
investigating ceramide synthase 2 (CerS2), which introduces
very-long-chain acyl-groups into ceramides and is far more
abundant in the liver than other CerS isoforms. Haploinsuffi-
ciency for this enzyme altered the pattern of ceramide acylation
in the liver without affecting total ceramide levels, replacing very-
long-chain ceramides with long-chain C16-ceramides, likely due
to compensatory increases in transcripts encoding other CerS
isoforms. This altered acylation pattern rendered mice suscepti-
ble to diet-induced steatohepatitis and insulin resistance.
RESULTS AND DISCUSSION
Though CerS2 heterozygous (CerS2/+) mice have markedly
depleted transcript levels in many tissues (Figure 1A), they areMetabolism 20, 687–695, October 7, 2014 ª2014 Elsevier Inc. 687
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Figure 1. CerS2 Haploinsufficiency Predisposes Mice to Steatohepatitis and Insulin Resistance
(A) Quantitative PCR of the CerS2 gene expression in various tissue/organs in CerS2 heterozygous and wild-type mice. Relative mRNA expression is normalized
against b-actin mRNA (n = 3/group, mean ± SEM).
(B) Body weight development in CerS2 heterozygous mice versus wild-type controls over 12 weeks on normal chow diet and high-fat diet (n = 6/each group,
mean ± SEM).
(legend continued on next page)
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Ceramide Acylation and Hepatic Steatosisphenotypically similar to wild-type animals and showed identical
growth curves, whether on normal chow or an obesogenic (e.g.,
high fat/high carbohydrate) diet (Figure 1B). The CerS2/+ mice
were metabolically indistinguishable from wild-type animals
when fed a chow diet. However, the loss of the single CerS2
allele rendered the mice highly susceptible to maladaptive
metabolic perturbations when placed on the obesogenic diet.
CerS2/+ mice demonstrated increased liver (1) weight (Fig-
ure 1C), (2) triglycerides (Figures 1D and 1E), and (3) macro-
phages (Figure 1D). Increased circulating levels of liver enzymes
ALT (Figure 1G) and AST (Figure 1H) and elevated plasma
cholesterol (Figure 1I) suggested that this combination of genetic
and environmental interventions induced liver damage. Of note,
however, both were required to induce steatosis, and neither did
so independently. On the obesogenic diet, the CerS2/+ mice
also displayed slightly impaired glucose tolerance (Figure 1L)
and evidence of insulin resistance including higher fed (Figure 1J)
and fasted (Figure 1K) insulin, increased circulating insulin during
a glucose tolerance test (Figure 1M), and decreased responsive-
ness to insulin during an insulin tolerance test (Figure S1H). Indi-
rect calorimetry revealed that the heterozygotes showed no
noticeable change in respiratory exchange ratio or oxygen con-
sumption. Though the heterozygotes appeared indistinguishable
from their wild-type littermates and healthy in appearance, they
had markedly decreased ambulatory activity (Figure S1). The
CerS2/+ mice displayed an increased ratio of fat to lean mass
(Figure 1N). There was mild insulin resistance as assessed by
an insulin tolerance test and small changes in insulin signaling
to the anabolic intermediate Akt/PKB in the livers of the CerS2/+
mice on the high-fat diet (Figures S1H and S1I). Moreover, liver
cells from the CerS2/+ mice on the obesogenic diet were under-
going apoptosis, as evidenced by the appearance of cleaved
poly (ADP-ribose) polymerase (PARP) (Figure S1J), though we
don’t know whether this is a cause or effect of the pathology.
Collectively, these data strongly dismiss the idea that CerS2
would be a good therapeutic target for combating diseases
associated with obesity, but raise the interesting possibility
that patterns of ceramide acylation could be an important deter-
minant of metabolic disease susceptibility. Tomeasure acylation
patterns directly in livers of the wild-type and CerS2/+ mice, we
obtained a comprehensive sphingolidomic profile bymass spec-
troscopy. As depicted in the heat map in Figure 2A, as well as
Figures 2C–2F and Figures S4C–S4E, acylation patterns were
greatly altered in the livers of the CerS2/+ mice. For each
sphingolipid class measured, the heterozygotes demonstrated
a decrease in one or more very-long-chain species (e.g., ceram-
ides, dihydroceramides, sphingomyelins, glucosylceramides,(C) Liver tissue weights in CerS2 heterozygous and wild-type mice.
(D) Photographs showing increased liver size in CerS2 heterozygous mice (a), Ce
hematoxylin and eosin (b) and oil red O (c), and immunohistochemistry using an
(E) Liver TG in CerS2 heterozygous and wild-type mice.
(F) qPCR of Fsp27 mRNA in liver of CerS2 heterozygous and wild-type mice. Re
(G–I) Plasma levels of liver enzymes in CerS2 heterozygous andwild-typemice. AL
(J) Fed (nonfasted/random) insulin.
(K) Fasted (6 hr) insulin.
(L) Blood glucose concentrations measured at various times after i.p. administra
(M) Plasma insulin concentrations were measured at various times after i.p. adm
(N) Whole-body fat measurement (MRI scan). n = 6, values are expressed as me
Celletc.). Of particular note, we saw a striking increase in CerS sub-
strates sphingosine and sphinganine and a reduction in the CerS
product dihydroceramides. Nonetheless, the CerS2/+ mice
contained considerably more C16-containing sphingolipids,
possibly resulting from a compensatory increase in CerS5 and
CerS6 transcripts (Figure 2B). Pretreating the CerS2/+ mice
with the ceramide synthesis (i.e., serine palmitoyltransferase) in-
hibitor myriocin reversed the phenotype (Figure S2), revealing
that it was the accumulation of the C16-ceramides or ceramide
metabolites that was pathogenic and that the metabolic abnor-
malities in CerS2/+ mice were not driven by the absence of
very-long-chain ceramides.
Transcriptomic analysis of genes involved in lipid synthesis or
metabolism in the liver revealed changes in a subset of genes in
the CerS2/+ mice, including PPARg and some lipid uptake
genes (e.g., CD36), but few changes in genes involved with fatty
acid synthesis (Table S1). No evidence existed for a concerted
increase in genes downstream of SREBP or ChREBP, transcrip-
tion factors involved in lipogenesis. Though there was an in-
crease in PPARg and a small subset of its target genes, and
though there are a few reports of sphingolipids being agonists
of PPARs (Jiang et al., 2009; Tsuji et al., 2009; Van Veldhoven
et al., 2000), we saw no evidence that ceramides bound the tran-
scription factor in vitro (Figure S3A). The most notable change in
transcripts was in the lipid droplet protein FSP27, which was
elevated nearly 40-fold in livers of the CerS2/+ mice fed the
high-fat diet (Figure 1F).
Having largely ruled out transcriptional alterations as a mech-
anism for the triglyceride accumulation in the CerS2/+ mice fed
the high-fat diet, we evaluated whether the lipid accumulation
could be due to impaired synthesis and secretion of very-low-
density lipoproteins (VLDLs). Though circulating triglycerides
were diminished in the CerS2/+ mice, the animals displayed
increased secretion of VLDLs (Figure S3B), suggesting that
impaired lipopoprotein synthesis or secretion was unlikely to
account for the steatosis in the CerS2/+ mice.
We next turned to a primary hepatocyte system to evaluate
whether the effect was cell autonomous and to further probe
mechanism. Indeed, hepatocytes isolated from CerS2/+
mice on a chow diet accumulated far more triglycerides than
wild-type counterparts, particularly after challenge with exoge-
nous fatty acid (i.e., oleate) (Figure 3A). Additionally, targeted
metabolomic profiling of livers obtained from the CerS2/+
mice on the high-fat diet revealed that they had elevated levels
of certain acylcarnitines, particularly a medium-chain acylcarni-
tine implicated in cardiovascular disease (Figure 3B) (Shah
et al., 2012). Since the accumulation of acylcarnitines canrS2 heterozygous and wild-type mouse liver histological sections stained with
antibody against the F4/80 antigen found in murine macrophages (d).
lative mRNA expression is normalized against b-actin mRNA.
T, alanine aminotransferase; AST, aspartate aminotransferase and cholesterol.
tion of glucose (t = 0) to 6 hr fasted CerS2 heterozygous and wild-type mice.
inistration of glucose.
an ± SEM. *p < 0.05; **p < 0.001; ***p < 0.0001.
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Figure 3. CerS2 Haploinsufficiency Impairs
Lipid Oxidation and Electron Transport
Chain Activity
(A) Assessment of lipid accumulation in isolated
primary hepatocytes in culture. Representative
photomicrographs (left) and quantitative densi-
tometry (right) of oil red O-stained primary hepa-
tocytes isolated from CerS2 heterozygous and
wild-type mice incubated in the absence or pres-
ence of oleic acid (OA, 200 mM) for 18 hr.
(B) Mass spectrometric quantitative analysis of
medium-chain acylcarnitine species in the livers of
wild-type or CerS2 heterozygous mice fed normal
chow or a high-fat diet (HFD).
(C) Fatty acid oxidation was measured in primary
hepatocytes in culture of CerS2 heterozygous and
wild-type mice by a Seahorse XF24 extracellular
flux analyzer. Cellular oxygen consumption rates
(OCR) were measured from basal rate and after
addition of palmitic acid and then the carnitine
palmitoyltransferase inhibitor etomoxir.
(D) Oxygen consumption rates (OCR) were
measured in primary hepatocytes from CerS2
heterozygous and wild-type mice by a Seahorse
XF24 extracellular flux analyzer. Following a period
of measurement to reveal basal respiration, oligo-
mycin was added to measure uncoupled respira-
tion. The subsequent addition of FCCP allowed for
the quantification of respiratory capacity, and the
addition of rotenone and antimycin A, which block
both complex I and II, allowed for determination of
residual respiration.
(E) Respiratory oxygen flux of each ETC complex
was measured in primary hepatocytes in real time
and expressed as picomoles of O2 per second per
million of cells using theOROBOROSOxygraph-2k
respirometer. Values are expressed as n = 6,
mean ± SEM. *p < 0.05; **p < 0.001; ***p < 0.0001.
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Ceramide Acylation and Hepatic Steatosissuggest incomplete lipid oxidation (Koves et al., 2008), we tested
whether defects in mitochondrial function could serve as the
primary mechanism underlying the steatosis in the CerS2/+
mice. Hepatocytes from CerS2/+ mice on a chow diet showed
markedly diminished rates of fatty acid oxidation (Figure 3C).
The CerS2/+ hepatocytes had decreased basal respiration,
ATP turnover, and maximal and spare respiratory capacity (Fig-
ure 3D). There was no change in mitochondrial DNA content in
any of the four groups (data not shown). We next analyzed the
activity of electron transport chain complexes in the isolated
primary hepatocytes. While complex 1 was indistinguishableFigure 2. CerS2 Haploinsufficiency Alters Sphingolipid Acylation Patterns
(A–F) Mass spectrometric quantitative analysis of sphingolipid species in liver of CerS2 heterozygous mice
depicted in the heat map. (B) Quantitative PCRs of the CerS2, CerS5, and CerS6 mRNA levels in liver of C
Ceramide, glucosylceramide, and sphingomyelin levels in the heterozygous mice are shown in (C), (D), and
showing lipids of each class is shown in (F). Values are expressed as n = 6, mean ± SEM. *p < 0.05; **p < 0.001
mice (CerS2 het) were maintained on either standard chow (chow) or obesogenic high-fat/high-sucrose die
Cell Metabolism 20, 687–69in mitochondria isolated from CerS2/+
mice compared to wild-type littermates,
complexes 2 and 4 showed markedly
decreased activity in the heterozygotes
(Figure 3E). This compromised complex2 and 4 activity was associated with reduced levels of total
ATP in the CerS2/+ hepatocytes (Figure S4A). To test whether
ceramides themselves could alter complex activity in vivo, we
treated wild-type C57BL/6J animals with myriocin for 2 weeks
and then measured activity of electron transport chain com-
plexes in primary hepatocytes isolated from these animals. Inhi-
bition of de novo ceramide synthesis enhanced complex 4
activity (Figure S4B). Collectively, these data suggest that the
triglyceride accumulation evident in the CerS2/+ mice was likely
due to impaired lipid oxidation resulting from C16-sphingolipid-
induced defects in the electron transport chain.and wild-type mice. (A) Sphingolidomic profile is
erS2 heterozygous and wild-type mice are shown.
(E), respectively. Complete sphingolidomic profile
; ***p < 0.0001. Wild-type and CerS2 heterozygous
t (HFD).
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Figure 4. Overexpression of Ceramide
Synthase 6 Recapitulates the Phenotype
of CerS2 Haploinsufficiency in Primary
Hepatocytes
(A–C) Mass spectrometric quantitative analysis of
sphingolipid species in primary hepatocytes
treatedwith recombinant adenoviruses expressing
GFP or wild-type murine CerS6 using recombinant
adenoviruses: (A) ceramide species, (B) dihy-
droceramide species, and (C) glucosylceramide
species.
(D) Akt phosphorylation was assessed by western
blotting following treatment with insulin (10 min,
100 nM).
(E) Representative photomicrographs of oil red
O-stained primary hepatocytes overexpressing
GFP or CerS6 using the aforementioned adenovi-
ruses. Cells were incubated in the absence or
presence of oleic acid (OA, 200 mM) for 18 hr.
(F) Respiratory oxygen flux was measured in pri-
mary hepatocytes in real time and expressed as
percent oxygen consumption rate (OCR) using the
OROBOROS Oxygraph-2k respirometer. Values
are expressed as n = 3, mean ± SEM. *p < 0.05;
**p < 0.001; ***p < 0.0001.
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accounted for the altered electron transport chain activity, we
overexpressed CerS6, which makes C16-ceramides, in primary
hepatocytes isolated from C57BL6/J mice using recombinant
adenoviruses. The expression of CerS2 in primary hepatocytes
had relatively small effects on the sphingolipidome, probably
owing to the large amount of endogenous protein already pre-
sent (data not shown). The overexpression of viruses encoding
CerS6 markedly increased C16 sphingolipids while lowering
levels of the longer-chain ones derived from CerS2, thus not
changing total sphingolipid levels (Figures 4A–4C). The changes
appeared to be restricted to sphingolipids, as phosphatidylcho-
line acylation patterns (data not shown) did not change. Levels of
sphingosine and sphinganine were markedly reduced, confirm-
ing that the overexpressed viruses were probably increasing
flux through the sphingolipid synthesis pathway (data not
shown). To test whether CerS6 overexpresssion was sufficient
to drive hepatic lipid accumulation, we measured insulin
signaling and triglyceride levels in the hepatocytes exposed to692 Cell Metabolism 20, 687–695, October 7, 2014 ª2014 Elsevier Inc.the CerS6-encoding adenovirus. CerS6
overexpression inhibited Akt/PKB activa-
tion (Figure 4D) and promoted triglyceride
accumulation (Figure 4E). CerS6 overex-
pression also inhibited complex II of the
electron transport chain (Figure 4F), iden-
tifying it as the synthase that produces
the pool of C16-ceramides that alter mito-
chondrial function.
The finding that CerS6 impaired com-
plex activity is consistent with data
recently generated by the Bru¨ning group,
which found that knockout of CerS6 pro-
vided protection from insulin resistance
(Turpin et al., 2014). These complemen-tary studies originated independently, while coming to strikingly
similar conclusions that CerS6-derived C16-ceramides are
involved in metabolic disease and impair lipid oxidation.
Though these studies clearly identify the liver as a target of
C16-ceramides, we cannot rule out roles in other tissues. In addi-
tion to CerS2 being highly expressed in the liver and kidney, it is
also highly expressed in brown adipose tissue. We note, how-
ever, that we observed no effects in total energy expenditure
or change in body weight; hence, we believe that our phenotype
is likely to result predominantly from changes in the liver. Also of
note, adenoviral expression of CerS6 in hepatocytes inhibited
mitochondrial function and promoted triglyceride production,
confirming cell autonomy.
A clear difference in our study compared with others
involving CerS knockouts is the reliance on heterozygotes,
rather than homozygous null animals. The heterozygote is a
much better mimic both of a drug effect and of genetic muta-
tions (see below), and most of the global CerS knockouts
have shown many health abnormalities owing to the absolute
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are not present in the heterozygotes. Moreover, the metabolic
dysfunction in the mice studied herein requires both genetic
(i.e., deletion of a CerS2 allele) and environmental (i.e., obeso-
genic diet) insults.
Nonetheless, noting the differences and similarities between
the heterozygotes and homozygous null animals reveals
much about cellular mechanisms and reinforces the idea that
altering C16/C22–C24 ratios markedly affects cellular function.
The homozygous null CerS2 mice, unlike the heterozygotes,
demonstrate on a chow diet numerous liver abnormalities
(e.g., hepatopathy, hepatocyte death, and recurrent regenera-
tion) (Pewzner-Jung et al., 2010a, 2010b), markedly reduced
body weight (Pewzner-Jung et al., 2010a, 2010b), and a con-
trasting decrease in lipid accumulation and uptake in the liver
(Park et al., 2014). Nonetheless, they similarly displayed
compensatory increases in C16-ceramides (Pewzner-Jung
et al., 2010a, 2010b) that were associated with hepatic insulin
resistance (Park et al., 2013) and disruption of the mitochon-
drial respiratory chain (Zigdon et al., 2013). The latter observa-
tions reinforce the mechanism proposed here, that C16
accumulation both alters insulin signaling to Akt/PKB and im-
pairs activity of the electron transport chain complexes. Anal-
ysis of available genome-wide association studies reveals the
existence of a prevalent single-nucleotide polymorphism in
the human CerS2 gene that is associated with indicators of
insulin resistance or impaired glucose tolerance. This common
natural variant leads to an amino acid substitution at position
115. rs267738 SNP is a missense SNP at codon position 2
that changes the amino acid glutamate to alanine; this is not
a conservative change. The mutation replaces a medium-sized,
acidic amino acid with a small, hydrophobic one at position
115, which falls in a cytoplasmic topological domain and a
DNA binding homeobox domain (2012). Thus, we speculate
that this variant may impair function of CerS2 encoded by
one allele in a manner that is recapitulated in the heterozygous
mice. Studies on the functional consequences of this mutation
are underway.
The other clear distinction here from most studies investi-
gating the intersection of ceramides and hepatic steatosis and
metabolic dysfunction is the focus on acyl-chain composition,
rather than levels of all ceramide species. One of the first studies
to demonstrate that the acyl-chain composition of ceramides
had functional consequences was from Menuz et al. in
C. elegans, whereby they found that changing the acyl composi-
tion altered sensitivity to hypoxia, though total levels of ceram-
ides were unchanged (Menuz et al., 2009). Few have tried this
approach in mammals, let alone as it relates to metabolic dis-
ease. The Schmitz-Peiffer group overexpressed each of the syn-
thases in cultured myotubes and found a paucity of effects
compared to increasing de novo synthesis with exogenous fatty
acids (Frangioudakis et al., 2013). Indeed, we similarly found
small effects when we expressed the enzymes in myotubes
(data not shown), as compared to the dramatic changes
observed in hepatocytes.
Though inhibitors of de novo ceramide synthesis pathway
have shown remarkable efficacy when given to rodents, ap-
proaches involved thus far have all involved inhibition of global
sphingolipid production. With nearly 4,000 sphingolipids knownCellto be present in mammalian cells (http://www.lipidmaps.org),
many of which play essential roles in tissue function, the question
of whether one can safely and effectively titrate ceramides into a
healthier range without adverse health effects has deterred
efforts to aggressively pursue these enzymes as therapeutic
targets. A more detailed understanding of which lipids are path-
ogenic offers new strategies for pharmaceutical or nutritional
intervention and a better understanding of the etiology of meta-
bolic disease. The studies herein strongly suggest that C16-ce-
ramides should specifically be targeted for reduction, and they
identify CerS6 as a possible therapeutic target for combating
metabolic disease.
EXPERIMENTAL PROCEDURES
Animals
CerS2/+ mice were generated from embryonic stem cells harboring a gene
trap (GT) retroviral vector insertion in the first intron of the CerS2 gene (Pewz-
ner-Jung et al., 2010b). Mice were placed on standard chow or a high-fat diet
containing 60 kcal% (D12492; Research Diets, Inc.) at 6 weeks of age. Studies
were conducted in accordance with the principles and procedures outlined in
the National Institutes of Health Guide for the Care and Use of Laboratory
Animals and were approved by the Institutional Animal Care and Use Commit-
tee (IACUC) at the Duke-National University of Singapore Graduate Medical
School.
Intraperitoneal Glucose Tolerance Test and Insulin Tolerance Test
Mice were fasted for 6 hr and dosed with 1.5 g/kg of body weight of glucose
(G7021, Sigma) or 0.75 U/kg of bodyweight of insulin (Actrapid, Novo Nordisk).
Blood glucose was measured with Bayer Contour glucometer, and plasma
samples were collected for insulin test with Insulin (Mouse) Ultrasensitive
ELISA kit (ALPCO Diagnostics).
Quantitative Real-Time PCR
Total RNA was extracted from tissues by using TRIzol (Invitrogen) followed by
RNA-Free DNase treatment and purification (QIAGEN) according to the man-
ufacturer’s recommendations. Quantitative real-time PCR was performed by
following the instructions accompanying the QIAGEN QuantiFast SYBR Green
PCR kit and using a QIAGEN QIAcube.
Primary Hepatocyte Isolation
Hepatocytes were isolated from 12-week-old wild-type and CerS2/+ mice
maintained on a chow diet (Martı´nez-Clemente et al., 2010). Isolated hepato-
cytes were plated on collagen I-coated plates (Sigma) and cultured inWilliam’s
E medium supplemented with 10% FBS, 2 mM glutamine, 50 IU/ml penicillin,
50 mg/ml streptomycin, 1 mM insulin, 15mMHEPES, and 50 mMmercaptoetha-
nol. Primary hepatocyte viability was determined by trypan blue exclusion.
Cells were maintained in a humidified 5% CO2 incubator at 37
C.
Triglyceride Accumulation in Primary Hepatocytes
Hepatocytes were cultured in 12-well plates at a density of 4 3 105 cells/well.
The plated cells were incubated for 18 hr with either vehicle, rosiglitazone
(10 mM), and/or oleic acid (200 mM) in William’s E medium supplemented
with 25 mM d-glucose, 1.5% FFA-free BSA, and 1% FBS. At the end of the
incubation period, the hepatocytes were stained with oil red O and visualized
under a microscope.
Adenovirus Overexpression in Primary Hepatocytes
After cell attachment (3 hr), recombinant adenoviruses were added to primary
hepatocytes at a titer of moi = 300. All experiments were performed 20 hr after
addition of virus. Mouse CerS6 overexpression adenoviruses were procured
from ViraQuest Inc.
Fatty Acid Oxidation and Cellular Oxygen Consumption
Mitochondrial FAO rate and cellular oxygen consumption were measured us-
ing the Seahorse XF24 analyzer as per manufacturer’s protocol.Metabolism 20, 687–695, October 7, 2014 ª2014 Elsevier Inc. 693
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Mice were fasted for 5 hr, followed by intravenous injection of tyloxapol
(Sigma-Aldrich) at 500 mg/kg body weight. Aliquots of tail vein blood were
taken at different times for plasma TG determination.
Measurement of Mitochondrial Respiration Chain Function
Cells were harvested with trypsin, and half a million cells per milliliter were
assayed in 2 ml MiR05 medium (0.5 mM EGTA, 3 mM MgCl2, 60 mM K-lacto-
bionate, 20mM taurine, 10mMKH2PO4, 20mMHEPES, 110mM sucrose, and
1 g/l BSA [essentially fatty acid free]) using the OROBOROS Oxygraph-2k
respirometer. Respiratory oxygen flux was measured in real time and ex-
pressed as picomoles of O2 per second per million cells. Cells were permea-
bilized by digitonin. A total of 5 mM pyruvate plus 2 mM malate and 1 mM
ADP were added to stimulate complex I respiration. Rotenone (1 mM) and suc-
cinate (5 mM) were added to test complex II respiration. Ascorbate (2 mM) and
N,N,N,N-tetramethyl-p-phenylenediamine (TMPD, 0.5 mM) were used to test
complex IV respiration.
Lipidomic Profiling
To quantify levels of specific lipids, tissues were homogenized in 280 ml of cold
PBS. Ten microliters was used for protein measurement, and lipids were
extracted from 200 ml using ice-cold chloroform/methanol (1:2) for 1 hour
with vortexes every 15min. The organic phase was separated with 300 ml chlo-
roform and 100 ml Milli-Q water. The organic phase was collected into a fresh
tube, dried with a gentle nitrogen stream, and stored at 80C for liquid
chromatography/mass spectroscopy analysis as described previously
(Holland et al., 2011).
Statistics
Comparisons between two groups was done with Student’s t tests. Compar-
isons involving multiple groups were done using one-way analysis of variance
(ANOVA). A level of p < 0.05 was considered to be significant.
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